RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04084496, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 79 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed adenocarcinoma of the pancreas without distant metastases.

    Inclusion criterion 1

  3. ECOG ≤ 1

    Inclusion criterion 5

  4. Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L Platelets ≥ 90 x 109/L Hemoglobin ≥ 90 g/L

    Inclusion criterion 7

  5. Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in situ).

    Exclusion criterion 7

    Known HIV-positivity.

    Exclusion criterion 11

  6. Female and male patients > 18 and <=79 years using contraception

    Inclusion criterion 4

    Pregnant or lactating women

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04084496, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the pancreas without distant metastases.
  • Receive radical resection of pancreatic cancer
  • No prior cytostatic chemotherapy
  • Female and male patients > 18 and <=79 years using contraception
  • ECOG ≤ 1
  • Patient has adequate bone marrow and organ function
  • Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L Platelets ≥ 90 x 109/L Hemoglobin ≥ 90 g/L
  • Patient has adequate liver function AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis) Serum bilirubin ≤ 1.2 x ULN Creatinine ≤ 1.25 times ULN
  • Good compliance
  • Written informed consent

Exclusion Criteria:

  • Pregnant or lactating women
  • Distant metastasis.
  • Patients with severe gastrointestinal hemorrhage which need frequent blood transfusions.
  • Refuse to take appropriate contraceptive measures (including male patients).
  • Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.
  • Severe systemic disease out of control such as unstable or uncompensated respiratory, cardiac, liver, renal diseases.
  • Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in situ).
  • Psychiatric illness that would prevent the patient from giving informed consent.
  • Patient is concurrently using other antineoplastic agent
  • Patient has used investigational antineoplastic agent within 4 weeks prior to entry.
  • Known HIV-positivity.
  • No history of chronic diarrhea, nausea or vomit.
  • No ≥ grade 2 sensory peripheral neuropathy.
  • A history of transmural myocardial infarction (within 6 months prior to entry), congestive heart failure, and unstable angina.
  • Infectious disease or inflammation with body temperature ≥ 38 ℃.

Quoted from ClinicalTrials.gov, NCT04084496, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04084496, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04084496